The most recent earnings report from CSL Limited (ASX:CSL) was disappointing for shareholders. Despite the soft profit numbers, our analysis has optimistic about the overall quality of the income ...

With pressure piling on for CSL, the Australian vaccine and plasma specialist has elected to part ways with its CEO on the eve of its latest earnings announcement. Paul McKenzie, Ph.D., who’s served ...

It's been a sad week for CSL Limited (ASX:CSL), who've watched their investment drop 16% to AU$152 in the week since the company reported its interim result. Revenues came in 2.7% below expectations, ...

One day after CSL suddenly replaced its CEO, the company provided dismal financial figures that helped explain why. In its half-year report, CSL said its net profit plummeted (PDF) from $2 billion in ...

CSL taps ex-vaccine division head Gordon Naylor as interim CEO Appointment of Naylor is a salvage mission, says analyst CSL shares close 5% lower; co to report HY results on Wed Feb 10 (Reuters) - ...

CSL announced the exit of Paul McKenzie as chief executive. Senior executive Gordon Naylor appointed interim CEO. Shares of Australian biotech firm CSL plunged to an 8-year low Wednesday after it ...

BMW is rumored to be developing a new version of its M8 Coupe that will carry the revered CSL badge, and at first, it seems like a challenging undertaking for the M division. After all, CSL translates ...

CSL’s interim chief executive Gordon Naylor has pleaded with angry investors for more time to return the global healthcare giant to its former glory, saying he will look at selling or scaling back non ...

CSL has gotten the Memo about the value of recombinant polyclonal immunoglobulin (IgG) antibodies. The company is signing on to a collaboration and option agreement with Memo Therapeutics that could ...

CSL's underlying earnings fell in the first half, but management stuck to its full-year guidance and boosted the buy-back. The CSL Ltd (ASX: CSL) share price is in focus today after reporting ...

Australia's CSL is wielding the axe, cutting its workforce by 15% – around 3,000 positions – while announcing plans to spin its vaccines unit into a standalone company. The decision to demerge the CSL ...